Juan Li
4 Papers
Juan Li is an academic researcher. The author has contributed to research in topics: Internal medicine & Pemetrexed. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).
Yunpeng Yang,Zhehai Wang,Jian Fang,Qitao Yu,Baohui Han,Shundong Cang,Gongyan Chen,Xiaodong Mei,Zhixiong Yang,Rui Ma,M. Bi,Xiubao Ren,Jianying Zhou,Baolan Li,Yong Song,Jifeng Feng,Juan Li,Zhiyong He,Rui Zhou,Weimin Li,You Lu,Yingyi Wang,Lijun Wang,Nong Yang,Yan Zhang,Zhuang Yu,Yanqiu Zhao,Conghua Xie,Ying Cheng,Hui Zhou,Shuyan Wang,Donglei Zhu,Wen Zhang,Li Zhang +33 more
TL;DR: In Chinese patients with previously untreated locally advanced or metastatic nonsquamous NSCLC, the addition of sintilimab to chemotherapy of pemetrexed and platinum resulted in significantly longer PFS than that of chemotherapy alone with manageable safety profiles.
321
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)
Caicun Zhou,Lin Wu,Yun Fan,Zhehai Wang,Lianke Liu,Gongyan Chen,Li Zhang,Dingzhi Huang,Shundong Cang,Zhixiong Yang,Jianying Zhou,Chengzhi Zhou,Baolan Li,Juan Li,Min Fan,Jiuwei Cui,Yuping Li,H. Zhao,Jian Fang,Jianxin Xue,Chengping Hu,Ping Sun,Yingying Du,Hui Zhou,Shuyan Wang,Wen Zhang +25 more
TL;DR: In this article, the authors conducted a randomized, double-blind, phase 3 study to further compare the efficacy and safety of sintilimab with placebo, both in combination with GP.
220
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
Yunpeng Yang,Jiya Sun,Zhehai Wang,Jian Fang,Qitao Yu,Baohui Han,Shundong Cang,Gongyan Chen,Xiaodong Mei,Zhixiong Yang,Rui Ma,M. Bi,Xiubao Ren,Jianying Zhou,Baolan Li,Yong Song,Jifeng Feng,Juan Li,Zhiyong He,Rui Zhou,Weimin Li,You Lu,Hui Zhou,Shuyan Wang,Luyao Sun,Oscar Puig,Christoph Mancao,Bo Peng,Wenfeng Fang,Wei Xu,Li Zhang +30 more
TL;DR: Sintilimab plus chemotherapy significantly prolonged progression-free survival (PFS) compared with chemotherapy alone in nonsquamous NSCLC in the ORIENT-11 study as mentioned in this paper.
104
Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).
Shun Lu,Xiaorong Dong,Hong Jian,Jianhua Chen,Gongyan Chen,Yuping Sun,Yinghua Ji,Ziping Wang,Jianhua Shi,Junguo Lu,Shaoshui Chen,Guojun Zhang,Dongqing Lv,Chunling Liu,Juan Li,Xinmin Yu,Zhong Lin,Zhuang Yu,Zhehai Wang,Jiuwei Cui +19 more
TL;DR: A novel, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) with favorable pharmacologic properties that selectively inhibits both EGFR sensiti...